Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17732055 | 0.74 | PIK3CB (0.59) | PIK3CB | |
| Bay-1082439 SCHEMBL17735976 | 0.74 | PIK3CB (0.59) | PIK3CB | |
| SCHEMBL28895762 | 0.73 | PIK3CB (1.00) | PIK3CB | |
| Hydrochloric Acid SCHEMBL31060375 | 0.73 | PIK3CB (1.00) | PIK3CB | |
| SCHEMBL29360908 | 0.69 | PIK3CB (1.00) | PIK3CB | |
| SCHEMBL26504048 | 0.66 | PIK3CB (0.75) | PIK3CB | |
| Bay-1082439 SCHEMBL6731645 | 0.66 | PIK3CB (0.49) | PIK3CB | |
| Bay-1082439 SCHEMBL10245149 | 0.66 | PIK3CB (0.49) | PIK3CB | |
| Bay-1082439 SCHEMBL31060926 | 0.66 | PIK3CB (0.49) | PIK3CB | |
| Bay-1082439 SCHEMBL17735974 | 0.66 | PIK3CB (0.49) | PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024022234-A1 | USE OF PYRAZOLOPYRIDINE COMPOUND IN PREPARATION OF DRUG FOR TREATING BTK-RELATED DISEASES COMPRISING DISEASES OF CENTRAL NERVOUS SYSTEM | 成都嘉葆药银医药科技有限公司 | 2024-02-01 | — | — | WO | claimed |
| EP-4661884-A2 | CD4+ AND CD8+ SINGLE POSITIVE T CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | Clade Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-119365194-A | Use of pyrazolopyridines for the treatment of BTK related diseases including central nervous system diseases | 成都嘉葆药银医药科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024168160-A2 | CD4 + AND CD8 + SINGLE POSITIVE T CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | CLADE THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024022234-A1 | USE OF PYRAZOLOPYRIDINE COMPOUND IN PREPARATION OF DRUG FOR TREATING BTK-RELATED DISEASES COMPRISING DISEASES OF CENTRAL NERVOUS SYSTEM | 成都嘉葆药银医药科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2019195181-A9 | ANTIBODIES AND FRAGMENTS THEREOF THAT BIND HEPATITIS B VIRUS PROTEIN X | GILEAD SCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-4069729-A1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | Precision BioSciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022103758-A1 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | WO | disclosed |